765.85
+4.20%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Akums Drugs and Pharmaceuticals
Its shares trade on NSE under the ticker AKUMS.NS. It has been listed since 6 August 2024. In the fiscal year to 31 March 2026, it reported revenue of ₹43.59bn and net income of ₹2.55bn. At that date it held total assets of ₹54.47bn and shareholders' equity of ₹33.13bn.
Akums Drugs and Pharmaceuticals Ltd is a IN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in New Delhi, Delhi. The company went IPO on 2024-08-06. Akums Drugs and Pharmaceuticals Limited is an India-based pharmaceutical contract development and manufacturing company. The company offers a comprehensive range of pharmaceutical products and services in India and overseas. The company is focused on providing end-to-end product development and manufacturing solutions to its clients. Its segments include Contract Development and Manufacturing Operations (CDMO), Active Pharmaceutical Ingredient (API) and Branded and Generic formulations. CDMO segment includes the formulation research and development, preparation and regulatory filing of dossiers, manufacturing formulations on a contract basis, job work and testing services. API segment is engaged in the manufacture and sale of key starting materials, Intermediate and API products. Branded and Generic formulations segment is engaged in marketing and distribution of branded and generic pharmaceutical formulations. The company has manufactured 4,146 commercialized formulations across over 60 dosage forms.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 6 Aug 2024
- Employees
- 7,388
- Website
- akums.in ↗
Leadership
Pay as last reported
- Mr. Sumeet SoodChief Financial Officer₹13.2m
- Mr. Dharamvir MalikCompliance Officer, Company Secretary₹2.1m
- Mr. Sandeep JainManaging Director, Executive Director, since 2004₹53.7m
- Mr. Sanjeev JainManaging Director, Executive Director, since 2004₹54.2m
- Mr. Sanjay SinhaWhole Time Director, President - Operations, since 2022₹2.1m
- Mr. Sunil ThakurNon-Executive Director
- Ms. Matangi GowrishankarIndependent Director₹2.8m
- Mr. Kewal HandaIndependent Director₹3.0m
- Mr. Satwinder SinghIndependent Director₹500,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Akums Drugs and Pharmaceuticals Ltd employs 7,388 full-time employees in the Life Sciences Tools & Services industry.
- The company's CDMO segment provides end-to-end product development and manufacturing solutions.
- Akums Drugs and Pharmaceuticals Ltd operates in the Health Care sector with a focus on India and overseas markets.
Weaknesses
- The company's IPO listing date is 6 August 2024, indicating recent market entry.
- Akums Drugs and Pharmaceuticals Ltd has not yet established a significant presence in international markets beyond India.
- The company's business description mentions limited details on specific product lines or market share.
Opportunities
- The Life Sciences Tools & Services industry in India shows strong growth potential for pharmaceutical CDMO services.
- Expanding the API segment could leverage India's position as a global API manufacturing hub.
- Growing demand for branded and generic formulations in emerging markets presents new opportunities.
Threats
- Intense competition in the Indian pharmaceutical CDMO market may affect profit margins.
- Regulatory changes in the Health Care sector could impact manufacturing operations.
- Global supply chain disruptions might affect the availability of key materials for API production.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.